Page 4 - Vitro Diagnostics News Today

Shockwave Medical (NASDAQ:SWAV – Get Free Report) and Surmodics (NASDAQ:SRDX – Get Free Report) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, earnings, analyst recommendations, profitability and risk. Profitability This table compares Shockwave Medical and Surmodics’ net […]

Surmodics (NASDAQ:SRDX – Get Free Report) and Shockwave Medical (NASDAQ:SWAV – Get Free Report) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, earnings, risk and analyst recommendations. Risk and Volatility Surmodics has a beta of 1.05, […]

In-Vitro Diagnostics (IVDs) are medical equipment used to perform tests on bodily fluids such as blood, stool, urine, etc. to detect infections and diseases.

Sana Biotechnology (NASDAQ:SANA – Get Free Report) and Vitro Diagnostics (OTCMKTS:VODG – Get Free Report) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, earnings, valuation and dividends. Analyst Recommendations This is a summary of current […]

/PRNewswire/ -- The "Europe Next Generation IVD Market: Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.coms offering. The...

Surmodics (NASDAQ:SRDX – Get Free Report) issued an update on its FY 2024 earnings guidance on Thursday morning. The company provided earnings per share guidance of -1.170–0.870 for the period, compared to the consensus earnings per share estimate of -1.160. The company issued revenue guidance of $113.0 million-$117.0 million, compared to the consensus revenue estimate […]

Surmodics, Inc. , a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its first quarter ended December 31, 2023,...

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its first quarter ended December 31, 2023, and updated its financial guidance for fiscal year ending Septemb...

Surmodics (NASDAQ:SRDX – Get Free Report) updated its FY 2024 earnings guidance on Thursday. The company provided earnings per share guidance of -1.170–0.870 for the period, compared to the consensus earnings per share estimate of -1.160. The company issued revenue guidance of $113.0 million-$117.0 million, compared to the consensus revenue estimate of $119.3 million. Analyst […]

Company Raises Full-Year Guidance Following Strong Quarterly Performance